Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A Defronzo

Showing results (61-70 of 313) with videos related to

Pageof 32
Sort By:
Trends in Endocrinology and Metabolism: TEM|November 23, 2016
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in DiabetesGiovanna Muscogiuri, Ralph A DeFronzo, Amalia Gastaldelli, et al.
The Journal of Clinical Endocrinology and Metabolism|August 7, 2024
Pre-Prediabetes: Insulin Resistance Is Associated With Cardiometabolic Risk in Nonobese Patients (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes & Vascular Disease Research|February 2, 2019
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesRalph A DeFronzo, Silvio Inzucchi, Muhammad Abdul-Ghani, et al.
Diabetes Care|December 29, 2006
Muscle and liver insulin resistance indexes derived from the oral glucose tolerance testMuhammad A Abdul-Ghani, Masafumi Matsuda, Bogdan Balas, et al.
Diabetes Care|March 27, 2007
What is the best predictor of future type 2 diabetes?Muhammad A Abdul-Ghani, Ken Williams, Ralph A DeFronzo, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|August 7, 2015
Novel Agents for the Treatment of Type 2 DiabetesRalph A DeFronzo, Curtis L Triplitt, Muhammad Abdul-Ghani, et al.
Diabetes Care|September 24, 2008
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyRalph A DeFronzo, Penny R Fleck, Craig A Wilson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 25, 2007
Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazoneEstela Wajcberg, Apiradee Sriwijitkamol, Nicolas Musi, et al.
Diabetes Care|May 22, 2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME StudyMuhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, et al.
Diabetes Care|November 25, 2004
Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjectsEstela Wajcberg, Yoshinori Miyazaki, Curtis Triplitt, et al.
Pageof 32

Showing results (61-70 of 313) with videos related to

Sort By:
Pageof 32
Trends in Endocrinology and Metabolism: TEM|November 23, 2016
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in DiabetesGiovanna Muscogiuri, Ralph A DeFronzo, Amalia Gastaldelli, et al.
The Journal of Clinical Endocrinology and Metabolism|August 7, 2024
Pre-Prediabetes: Insulin Resistance Is Associated With Cardiometabolic Risk in Nonobese Patients (STOP DIABETES)John Armato, Ralph A DeFronzo, Muhammad Abdul-Ghani, et al.
Diabetes & Vascular Disease Research|February 2, 2019
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetesRalph A DeFronzo, Silvio Inzucchi, Muhammad Abdul-Ghani, et al.
Diabetes Care|December 29, 2006
Muscle and liver insulin resistance indexes derived from the oral glucose tolerance testMuhammad A Abdul-Ghani, Masafumi Matsuda, Bogdan Balas, et al.
Diabetes Care|March 27, 2007
What is the best predictor of future type 2 diabetes?Muhammad A Abdul-Ghani, Ken Williams, Ralph A DeFronzo, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|August 7, 2015
Novel Agents for the Treatment of Type 2 DiabetesRalph A DeFronzo, Curtis L Triplitt, Muhammad Abdul-Ghani, et al.
Diabetes Care|September 24, 2008
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyRalph A DeFronzo, Penny R Fleck, Craig A Wilson, et al.
The Journal of Clinical Endocrinology and Metabolism|January 25, 2007
Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazoneEstela Wajcberg, Apiradee Sriwijitkamol, Nicolas Musi, et al.
Diabetes Care|May 22, 2016
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME StudyMuhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, et al.
Diabetes Care|November 25, 2004
Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjectsEstela Wajcberg, Yoshinori Miyazaki, Curtis Triplitt, et al.
Pageof 32